139 related articles for article (PubMed ID: 1683772)
1. Studies on the mechanism of action of A80915A, a semi-naphthoquinone natural product, as an inhibitor of gastric (H(+)-K+)-ATPase.
Dantzig AH; Minor PL; Garrigus JL; Fukuda DS; Mynderse JS
Biochem Pharmacol; 1991 Oct; 42(10):2019-26. PubMed ID: 1683772
[TBL] [Abstract][Full Text] [Related]
2. Studies on the mechanism of action of the gastric microsomal (H+ + K+)-ATPase inhibitors SCH 32651 and SCH 28080.
Scott CK; Sundell E; Castrovilly L
Biochem Pharmacol; 1987 Jan; 36(1):97-104. PubMed ID: 3026407
[TBL] [Abstract][Full Text] [Related]
3. SK&F 96067 is a reversible, lumenally acting inhibitor of the gastric (H+ + K+)-ATPase.
Keeling DJ; Malcolm RC; Laing SM; Ife RJ; Leach CA
Biochem Pharmacol; 1991 Jun; 42(1):123-30. PubMed ID: 1648919
[TBL] [Abstract][Full Text] [Related]
4. Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases.
Mattsson JP; Väänänen K; Wallmark B; Lorentzon P
Biochim Biophys Acta; 1991 Jun; 1065(2):261-8. PubMed ID: 1647821
[TBL] [Abstract][Full Text] [Related]
5. By 1023/SK&F 96022: biochemistry of a novel (H+ + K+)-ATPase inhibitor.
Simon WA; Keeling DJ; Laing SM; Fallowfield C; Taylor AG
Biochem Pharmacol; 1990 Jun; 39(11):1799-806. PubMed ID: 2160820
[TBL] [Abstract][Full Text] [Related]
6. Substituted thieno[3,4-d]imidazoles, a novel group of H+/K(+)-ATPase inhibitors. Differentiation of their inhibition characteristics from those of omeprazole.
Beil W; Staar U; Sewing KF
Eur J Pharmacol; 1990 Oct; 187(3):455-67. PubMed ID: 1963594
[TBL] [Abstract][Full Text] [Related]
7. SCH 28080 is a lumenally acting, K+-site inhibitor of the gastric (H+ + K+)-ATPase.
Keeling DJ; Laing SM; Senn-Bilfinger J
Biochem Pharmacol; 1988 Jun; 37(11):2231-6. PubMed ID: 2837231
[TBL] [Abstract][Full Text] [Related]
8. The mechanism for inhibition of gastric (H+ + K+)-ATPase by omeprazole.
Lorentzon P; Eklundh B; Brändström A; Wallmark B
Biochim Biophys Acta; 1985 Jul; 817(1):25-32. PubMed ID: 2988621
[TBL] [Abstract][Full Text] [Related]
9. Omeprazole, a specific inhibitor of gastric (H+-K+)-ATPase, is a H+-activated oxidizing agent of sulfhydryl groups.
Im WB; Sih JC; Blakeman DP; McGrath JP
J Biol Chem; 1985 Apr; 260(8):4591-7. PubMed ID: 2985559
[TBL] [Abstract][Full Text] [Related]
10. Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749.
Nagaya H; Satoh H; Kubo K; Maki Y
J Pharmacol Exp Ther; 1989 Feb; 248(2):799-805. PubMed ID: 2537417
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of the K+-competitive H+,K+-ATPase inhibitor AZD0865 in isolated rat gastric glands.
Kirchhoff P; Andersson K; Socrates T; Sidani S; Kosiek O; Geibel JP
Am J Physiol Gastrointest Liver Physiol; 2006 Nov; 291(5):G838-43. PubMed ID: 16798725
[TBL] [Abstract][Full Text] [Related]
12. Reversible inhibition of rat gastric H+/K+-ATPase by T-330, 2-[2-dimethylaminobenzyl)sulfinyl]-1-(3-methylpyridine-2-yl)imidazole.
Kinoshita M; Saito N; Noto T; Tamaki H
J Pharmacol Exp Ther; 1996 Apr; 277(1):28-33. PubMed ID: 8613931
[TBL] [Abstract][Full Text] [Related]
13. Studies on the mechanism of action of omeprazole.
Keeling DJ; Fallowfield C; Milliner KJ; Tingley SK; Ife RJ; Underwood AH
Biochem Pharmacol; 1985 Aug; 34(16):2967-73. PubMed ID: 2992525
[TBL] [Abstract][Full Text] [Related]
14. Interaction of a K(+)-competitive inhibitor, a substituted imidazo[1,2a] pyridine, with the phospho- and dephosphoenzyme forms of H+, K(+)-ATPase.
Mendlein J; Sachs G
J Biol Chem; 1990 Mar; 265(9):5030-6. PubMed ID: 2156860
[TBL] [Abstract][Full Text] [Related]
15. AHR-9294: a novel inhibitor of H,K-ATPase antagonizes gastric HCl secretion in vivo.
Reenstra WW; Pinkus LM; Bailey J; Smith WL; Droppleman D; Sancilio LF; Forte JG
J Pharmacol Exp Ther; 1992 May; 261(2):737-45. PubMed ID: 1315865
[TBL] [Abstract][Full Text] [Related]
16. SCH 28080 is a more selective inhibitor than SCH 32651 at the K+ site of gastric K+/H+-ATPase.
Beil W; Staar U; Sewing KF
Eur J Pharmacol; 1987 Jul; 139(3):349-52. PubMed ID: 2822435
[TBL] [Abstract][Full Text] [Related]
17. Reversible and potent uncoupling of hog gastric (H(+)+K(+))-ATPase by prodigiosins.
Matsuya H; Okamoto M; Ochi T; Nishikawa A; Shimizu S; Kataoka T; Nagai K; Wasserman HH; Ohkuma S
Biochem Pharmacol; 2000 Dec; 60(12):1855-63. PubMed ID: 11108801
[TBL] [Abstract][Full Text] [Related]
18. Luminal acidification in K-replete OMCDi: contributions of H-K-ATPase and bafilomycin-A1-sensitive H-ATPase.
Armitage FE; Wingo CS
Am J Physiol; 1994 Sep; 267(3 Pt 2):F450-8. PubMed ID: 8092259
[TBL] [Abstract][Full Text] [Related]
19. The specificity of omeprazole as an (H+ + K+)-ATPase inhibitor depends upon the means of its activation.
Keeling DJ; Fallowfield C; Underwood AH
Biochem Pharmacol; 1987 Feb; 36(3):339-44. PubMed ID: 3028428
[TBL] [Abstract][Full Text] [Related]
20. [Possible mechanisms for (H+ + K+)-ATPase inhibition by proton pump inhibitors, omeprazole, lansoprazole and SCH 28080].
Nagaya H; Satoh H
Nihon Rinsho; 1992 Jan; 50(1):26-32. PubMed ID: 1311786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
